Haemodynamic effects of levosimendan following cardiac surgery
A Slezina, Eva Strīķe, M Bekers-Anchipolovskis
Abstract
Open-access reader
A Slezina, Eva Strīķe, M Bekers-Anchipolovskis
Abstract
Open-access reader
Myocardial contractile function following cardiac surgery often requires inotropic support. Traditionally, phosphodiesterase inhibitors and catecholamines are used [ 1 , 2 ]. Levosimendan is a novel inotropic agent–calcium sensitizer that enhances myocardial contractility without increasing intracellular calcium and myocardial oxygen demand [ 3 ]. The aim of our study was to evaluate circulation following levosimendan infusion, to find out the efficiency of tissue oxygen supply and to evaluate other inotrope dosage rates during levosimendan infusion.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Myocardial contractile function following cardiac surgery often requires inotropic support. Traditionally, phosphodiesterase inhibitors and catecholamines are used [ 1 , 2 ]. Levosimendan is a novel inotropic agent–calcium sensitizer that enhances myocardial contractility without increasing intracellular calcium and myocardial oxygen demand [ 3 ]. The aim of our study was to evaluate circulation following levosimendan infusion, to find out the efficiency of tissue oxygen supply and to evaluate other inotrope dosage rates during levosimendan infusion.
Key concepts: Levosimendan, Inotrope, Medicine, Contractility, Cardiology, Hemodynamics, Cardiac function curve, Internal medicine